The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
985
October 11, 1996
View Complete Issue         Table of Contents 2019 
Dehydroepiandrosterone (DHEA)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dehydroepiandrosterone (DHEA)
October 11, 1996 (Issue: 985)
Dehydroepiandrosterone (DHEA) is an adrenal androgen now being marketed as a "food supplement"in health food stores. DHEA is not approved for any indication by the US Food and Drug Administration (FDA).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dehydroepiandrosterone (DHEA)
Article code: 985a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.